12 August 2020 in BMC Neurology
Background: Cerebral cryptococcomas is a rare form of central nervous system cryptococcosis. Most previous cases were mistaken for neoplasm before surgery. We present a case of cerebral cryptococcomas whose radiological profiles resembled demyelinating disease, especially tumefactive demyelinating lesion. Case presentation: A 40-year-old male was admitted for 1-week-long unconsciousness. Brain MRI revealed a rim-enhanced mass within the corpus callosum body. Central nervous system demyelinating disease was suspected. Empirical corticosteroid treatment led to some improvement, but his condition deteriorated 2 months later. Brain MRI revealed punctate new foci. Cryptococcus neoformans was detected in cerebrospinal fluid. Cryptococcus antigen test was positive in his current and previous cerebrospinal fluid samples. The patient died despite standard antifungal treatment. Conclusion: Diagnosis of cerebral cryptococcomas is challenging. It may mimic demyelinating diseases.
18 May 2026 in BMC Neurology
The classification of chronic inflammatory demyelinating polyneuropathy (CIDP) is evolving with the discovery of autoantibodies against nodal and paranodal proteins, leading to the recognition of "autoimmune nodopathies." While anti-neurofascin-155 (NF155) and anti-contactin-1 (CNTN1) antibodies are well-characterized, the phenotype of anti-gliomedin (GLDN) antibodies remains poorly defined. We present a comprehensive case to delineate its clinical and serological profile. We report a detailed longitudinal case of a patient with anti-GLDN antibody-positive CIDP, including clinical presentation, electrophysiological and imaging studies, serological testing, treatment response, and follow-up. A 48-year-old woman presented with an 11-month history of relapsing-remitting, symmetric sensorimotor polyneuropathy, triggered by immune-activating events. Electrodiagnostic studies confirmed a demyelinating polyneuropathy meeting definitive European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria. Cerebrospinal fluid (CSF) analysis showed marked albuminocytological dissociation (protein 1631 mg/L). Serology was positive for anti-GLDN IgG (cell-based assay titer 1:32). The patient exhibited an excellent but transient response to intravenous immunoglobulin (IVIg), leading to multiple relapses. Subsequent B-cell targeted therapy with rituximab resulted in sustained clinical stabilization, effective B-cell depletion, and negative conversion of anti-GLDN IgG antibody. This case suggests that anti-GLDN antibody-associated CIDP may be associated with a recognizable phenotype within the autoimmune nodopathy spectrum. Potential key features include a relapsing course following immune stimulation, markedly elevated cerebrospinal fluid protein, a unique pattern of robust but unsustained response to intravenous immunoglobulin (IVIg), and a favorable response to B-cell depletion therapy as evidenced by clinical remission and seroconversion.